Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

BiomX’s XMarker biomarker discovery platform to potentially inform Boehringer Ingelheim’s development of IBD therapeutics
Marks the second agreement between Boehringer Ingelheim and BiomX focused on IBD.